In my work, I always try to combine fundamental analysis and technical analysis. They are both important, especially on a topic as important as the covid vaccine. Johnson & Johnson is about to be marketed, after the approval of the EMA on 11 March. Exactly after the announcement, I bought the stock. The JnJ vaccine has a much lower distribution cost than Pfizer...
I love JNJ long and believe that they are going to be fine with the recent COVID-related dip. Their vaccine could do more damage than AstraZeneca's and governments will still buy it in order to herd the sheep. You need to understand that JNJ is so much more than a vaccine company. Expect this stock to go back up to the $167 level, as well as breaking the $170...
Only good news coming out of BNTX. Today came 100% effectiveness in 12-15 year olds. When Marburg facility comes online they will be making bank on 50% share with Pfizer. Targeting 128 Pfizer entry, then a push 150+ before a pullback Positions: 400 shares, 120/130c May, 150/160c June Lottos.
On PFIZER , H1 timeframe price is around a critical decision zone, so what can we expect here: 1. Global Recover: If the fundamentals are positive, then the chart will be bullish and we will go into the 1st scenario where price continues to trade inside the channel until it reaches the resistance zone were we can look for sell setups. 2. Failure: Unlike the...
Fundamental and Technical Analysis show this as a very strong buy candidate. I can see this hitting 930.00 within 8 Weeks.
Just interesting that Moderna (MRNA) was taking off while Pfizer (PFE) was declining.
Continuation play here in my opinion. Can expect this to travel up to around 20$ in the next few weeks. Trade safe! This is a high risk pick... Please like/share if you want to see more!
VBIV CEO Baxter said on a feb 5 2021 podcast that human trials were to begin in the next couple of weeks for their single dose monovalent covid vaccine vbi-2902, which received $56 Million from Canada to produce a vaccine. Today moderna announced forecasted sales of ~$18 Billion just from covid vaccine sales. Once VBi announces initiation of human trials for the...
Notice the major multi-year higher low formed in 2019, followed by the rounding basing pattern and subsequent breakout outside of the multi-year triangle. The higher low in 2019, before the Covid deflation crash, tells me the agriculture complex was already bottoming ahead of Covid and now has a full head of steam. Corn, Soybeans, Sugar, Fertilizer have all...
We're already in the midst of record runs in the equity and commodity markets but as bubbly as it seems, its not over. We are in an environment that not many people are familiar with. The last time Growth and Inflation on a global scale were accelerating as fast as they are now was immediately after World War 2. Previous commodity cycles were sparked by 1 or 2...
We talked about this trade since last year, it's time.
Hey guys so NVAX had a nice bounce today from its open at 240 and closed at 273.98. It was a solid day I'm not too happy about the volume though due to it being pretty low. The stock is not going to have a tremendous move if there is no volume. We need to have above average volume to see a nice spike above 300 again. Now with the EU news coming possibly end of...
CureVac - bullish - Q1 - mid-term possbile route - many shares have the same formation right now.. with a more likely breakout on top
Long swing play. Shown here on the weekly is a bullish falling wedge. Has seen quite the sell off perhaps in a 'sell the news' event following vaccine frenzy. But Pfizer isn't going anywhere.
I see a massive spike coming in really soon with NVAX, with the pullback continuing probably till 278 I see an explosion coming!! Around 450 a share is where I see NVAX landing! With RSI, MACD, and William % showing oversold levels I see a reverse coming next week to the uptrend. I hope I am right let us see.
Trade MRNA with caution and strict SL. It may blow past the resistance band, but there is a risk of a sharp turnaround due to the parabolic rise in price and valuation.
Extremely oversold, perfect consolidation for a final run to test the 4.97 resistance. Volume is bottoming off again as well, further confirming that this is the lowest we'll see it.
These companies are selected for composition "Moderna Vaccine" because 1.developed the vaccine 2.suppliers 3.distribution chain Weights are calculated by relative market cap.